Home » Stocks » IKNA

Ikena Oncology, Inc. (IKNA)

Stock Price: $16.05 USD -2.90 (-15.30%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $16.99 +0.94 (5.86%) Apr 9, 7:39 PM
Market Cap 555.14M
Revenue (ttm) 9.19M
Net Income (ttm) -44.26M
Shares Out 34.59M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $16.05
Previous Close $18.95
Change ($) -2.90
Change (%) -15.30%
Day's Open 18.97
Day's Range 15.75 - 19.02
Day's Volume 133,575
52-Week Range 15.75 - 37.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

1 week ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer...

2 weeks ago - Business Wire

Ikena Oncology, a phase 1 oncology biotech developing small molecule inhibitor therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Ikena Oncology, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About IKNA

Ikena Oncology is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned an... [Read more...]

Industry
Biotechnology
IPO Date
Mar 26, 2021
CEO
Mark Manfredi, Ph.D.
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
IKNA
Full Company Profile

Financial Performance

In 2020, Ikena Oncology's revenue was $9.19 million, a decrease of -33.15% compared to the previous year's $13.75 million. Losses were -$44.26 million, 163.2% more than in 2019.

Financial Statements